Skip to main content
All lobbying filings

BRIDGEBIO PHARMA, INC.

Lobbying for BRIDGEBIO PHARMA, INC. · Biotech company

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 19, 2026
Expenses
$510,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
California

Official filing document

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 1
Pharmacy

Orphan drug policies General issues and provisions related to PBM Reform General issues and provisions related to tariffs H.R.1532 and S.822 - Scientific EXPERT Act Priority for Pediatric Cures Act (H.R.10359)

 Bills named in this filing 3

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem